Target ALS was featured by Intersection on LinkNYC digital screens throughout May to celebrate ALS Awareness Month. Featuring five New Yorkers driving ALS research forward and five facts about our impact, the campaign helped amplify our mission to break down barriers to ALS research to find effective treatments.
Uniting For a Cure
The first set of features shared stories of New Yorkers connected to our mission who are driving ALS research forward. This group includes individuals from different stakeholder groups, including academia, pharma, the ALS community, and our Target ALS Board of Directors and Independent Review Committee, underscoring our commitment to radical collaboration across sectors to advance ALS research.
- Dan Doctoroff, Founder of Target ALS
- Fanny Elahi, MD, PhD, Associate Professor, Icahn School of Medicine at Mount Sinai and Member, Target ALS Independent Review Committee
- Jack Humphrey, PhD, Instructor, Department of Neuroscience, Icahn School of Medicine at Mount Sinai
- Hemali Phatnani, PhD, Faculty Member and Director of the Center for Genomics of Neurodegenerative Disease (CGND), New York Genome Center and Assistant Professor of Neurological Sciences, Columbia University
- Aarti Sharma, PhD, Director, Regeneron
Hope in Action
The second set of features shared facts about Target ALS’ impact on the ALS research landscape. Our Innovation Ecosystem model was built to break down barriers that slow or prevent meaningful progress in scientific research. These impact metrics represent that model in action, inspiring hope for a future where everyone with ALS lives.
- Over $80 million invested directly into groundbreaking ALS research.
- More than 675 ALS research projects funded — each bringing us closer to answers.
- 53% of our ALS research consortia have launched new drug discovery efforts.
- 10 clinical trials launched based on research powered by Target ALS.
- 6 biotech companies created to accelerate ALS research breakthroughs into real-world treatments.
We are incredibly grateful to Intersection for their partnership and for amplifying our mission this May.
